127 related articles for article (PubMed ID: 38128174)
1. Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register.
Molina-Collada J; Alonso F; Otero L; Bohórquez C; Díaz Torné C; Pérez García C; Blanco Madrigal JM; Vela P; Álvaro-Gracia JM; Castrejón I;
Semin Arthritis Rheum; 2024 Feb; 64():152341. PubMed ID: 38128174
[TBL] [Abstract][Full Text] [Related]
2. Incidence of dementia in patients with rheumatoid arthritis and association with disease modifying anti-rheumatic drugs - Analysis of a national claims database.
Sattui SE; Navarro-Millan I; Xie F; Rajan M; Yun H; Curtis JR
Semin Arthritis Rheum; 2022 Dec; 57():152083. PubMed ID: 36155968
[TBL] [Abstract][Full Text] [Related]
3. Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice.
Huss V; Bower H; Wadström H; Frisell T; Askling J;
Rheumatology (Oxford); 2022 May; 61(5):1810-1818. PubMed ID: 34324640
[TBL] [Abstract][Full Text] [Related]
4. Changes in Market Share of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Results from the Ontario Best-Practice Research Initiative Database.
Hepworth E; Movahedi M; Rampakakis E; Mirza R; Lau A; Cesta A; Pope J; Sampalis JS; Bombardier C
Curr Rheumatol Rev; 2021; 17(3):349-359. PubMed ID: 33308132
[TBL] [Abstract][Full Text] [Related]
5. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.
Silva-Fernández L; Lunt M; Kearsley-Fleet L; Watson KD; Dixon WG; Symmons DP; Hyrich KL;
Rheumatology (Oxford); 2016 Nov; 55(11):2033-2039. PubMed ID: 27550304
[TBL] [Abstract][Full Text] [Related]
6. The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs.
Cho SK; Lee J; Han M; Bae SC; Sung YK
Arthritis Res Ther; 2017 Dec; 19(1):277. PubMed ID: 29246243
[TBL] [Abstract][Full Text] [Related]
7. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
[TBL] [Abstract][Full Text] [Related]
8. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.
Simon TA; Boers M; Hochberg M; Baker N; Skovron ML; Ray N; Singhal S; Suissa S; Gomez-Caminero A
Arthritis Res Ther; 2019 Nov; 21(1):228. PubMed ID: 31703717
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Review of the safety of non-TNF inhibitor biologic and targeted synthetic drugs in rheumatic disease in pregnancy.
Nguyen H; Ahmed K; Luo W; Flint J; Giles I
Semin Arthritis Rheum; 2021 Dec; 51(6):1205-1217. PubMed ID: 34689007
[TBL] [Abstract][Full Text] [Related]
10. Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register.
Meissner Y; Schäfer M; Albrecht K; Kekow J; Zinke S; Tony HP; Strangfeld A
RMD Open; 2023 Oct; 9(4):. PubMed ID: 37880180
[TBL] [Abstract][Full Text] [Related]
11. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.
Strangfeld A; Hierse F; Rau R; Burmester GR; Krummel-Lorenz B; Demary W; Listing J; Zink A
Arthritis Res Ther; 2010; 12(1):R5. PubMed ID: 20064207
[TBL] [Abstract][Full Text] [Related]
12. Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence.
Singh N; Li CI
Curr Opin Rheumatol; 2021 May; 33(3):292-299. PubMed ID: 33741804
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
[TBL] [Abstract][Full Text] [Related]
14. Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study.
Simon TA; Suissa S; Boers M; Hochberg MC; Skovron ML; Askling J; Michaud K; Strangfeld A; Pedro S; Frisell T; Meissner Y; Dominique A; Gomez A
Semin Arthritis Rheum; 2024 Feb; 64():152240. PubMed ID: 37500379
[TBL] [Abstract][Full Text] [Related]
15. Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.
Liang H; Danwada R; Guo D; Curtis JR; Kilpatrick RD; Hendrickson B; Islam SS
RMD Open; 2019; 5(2):e001013. PubMed ID: 31673413
[TBL] [Abstract][Full Text] [Related]
16. Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme.
Frisell T; Bower H; Morin M; Baecklund E; Di Giuseppe D; Delcoigne B; Feltelius N; Forsblad-d'Elia H; Lindqvist E; Lindström U; Askling J;
Ann Rheum Dis; 2023 May; 82(5):601-610. PubMed ID: 36787994
[TBL] [Abstract][Full Text] [Related]
17. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
Buchbinder R; Van Doornum S; Staples M; Lassere M; March L
BMC Musculoskelet Disord; 2015 Oct; 16():309. PubMed ID: 26481039
[TBL] [Abstract][Full Text] [Related]
18. Different risk profiles of biologic agents for new-onset psoriasis in patients with rheumatoid arthritis.
Baganz L; Listing J; Kekow J; Eisterhues C; Wassenberg S; Zink A; Strangfeld A
Semin Arthritis Rheum; 2020 Feb; 50(1):36-41. PubMed ID: 31350056
[TBL] [Abstract][Full Text] [Related]
19. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study.
Kim SC; Pawar A; Desai RJ; Solomon DH; Gale S; Bao M; Sarsour K; Schneeweiss S
Semin Arthritis Rheum; 2019 Oct; 49(2):222-228. PubMed ID: 30967248
[TBL] [Abstract][Full Text] [Related]
20. Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With Meta-Analysis.
Wetzman A; Lukas C; Gaujoux-Viala C; Mamtani R; Barnetche T; Combe B; Morel J; Szafors P
Arthritis Care Res (Hoboken); 2023 Feb; 75(2):260-271. PubMed ID: 34549898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
